Mangalam Drugs And Organics Limited has informed the Exchange about Copy of Newspaper Publication

Revenue DeclineCompliance View source PDF

MANGALAM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-0.5%1-day move

₹30.55

prior close

₹29.94

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.0+0.0+0.0-0.5-2.0+2.0-0.2-3.9-5.1-7.2-3.2-8.1—

Up moveDown movePending

AI summary

Mangalam Drugs published audited financial results for Q4 and FY2026. The company reported total income of ₹2,328.95 lakhs for the year, down from ₹3,187.28 lakhs in FY2025. It posted a massive net loss of ₹4,381.42 lakhs for FY2026 compared to a net profit of ₹682.43 lakhs in the previous year. The quarterly loss for Q4 ended March 2026 stood at ₹1,306.04 lakhs. Basic EPS deteriorated to (₹27.68) from ₹4.37 in the prior year. The Board approved these results on May 14, 2026.

Likely market impact

The stock may face significant pressure as the company swung from profit to a massive loss, indicating severe operational challenges. Investors should monitor for further disclosures on reasons behind the sharp decline.